Pipeline - Rise Therapeutics

R-3750, R-2487, R-5280, and R-5780 are oral therapies targeting immune pathways for treating inflammatory bowel disease, rheumatoid arthritis, type 1 diabetes, and cancer, respectively. Each is in Phase 1 trials, focusing on safety, tolerability, and efficacy. Details for participation are available at NCT05666960, NCT05961592, and NCT06057454.